Pegcetacoplan Drug Asset Due Diligence Report 2026

This Pegcetacoplan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

116

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Pegcetacoplan can convert its Synthetic peptide, Cyclic Peptide profile and C3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Pegcetacoplan (query alias: pegcetacoplan)
Modality / target	Synthetic peptide, Cyclic Peptide; C3; C3 inhibitors
Highest global status	Approved
Originator	Apellis Pharmaceuticals, Inc.
Active developers	Swedish Orphan Biovitrum Japan KK, Apellis Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB

The MCP disease footprint includes C3 glomerulopathy, Glomerulonephritis, Membranoproliferative, Geographic Atrophy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-jRCT2071260009	Phase 3	募集前	20	AMDに伴うGAを有する日本人被験者を対象に、pegcetacoplanをIVT投与したときの安全性及び忍容性を評価する・TEAE（治験薬投与後に発現した有害事象）及び重篤なTEAEの発現率及び重症度
NCT07213960	Phase 2/3	Suspended	270	Phase 2: Evaluate the efficacy of APL2 in terms of change from baseline in log-transformed urine protein to creatinine ratio (uPCR)
NCT07215390	Phase 2	Recruiting	240	Change from baseline (CFB) in the area of artificial intelligence (AI)-based SD-OCT assessment of RPE lesion in the study eye

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN

Phase 3; n=55; evaluation: Positive. Reported fields: Composite renal end point: P-Value = 0.002; Composite renal end point: P-Value = 0.002

REAL-WORLD EFFECTIVENESS OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AFTER SWITCH FROM C5 INHIBITORS AMONG CEE COUNTRIES

Not Applicable; n=38; evaluation: Positive. Reported fields: ARC(24-week) = 124.0 10^9/L

FLOW CYTOMETRY IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RELEVANCE OF THE MONITORIZATION OF THE ERYTHROID CLONE SIZE IN PATIENTS WITH COMPLEMENT INHIBITORS THERAPY.

Not Applicable; n=10; evaluation: Positive. Reported fields: Adverse Event: EVH = During a median follow-up of 49.5 months, 3/10 patients required therapy modification due to persistent anemia compatible with EVH.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Pegcetacoplan addresses C3 glomerulopathy, Glomerulonephritis, Membranoproliferative, Geographic Atrophy. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide, Cyclic Peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 7 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-03-31	Biogen Completes Acquisition of Apellis Pharmaceuticals	Approved	US$5,830.0M stated total
2025-07-01	Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)	Approved	Financial terms not disclosed
2024-01-29	Acino signs an exclusive distribution agreement with the Swedish biopharmaceutical company Sobi in Kazakhstan	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Uses of Anti-c3 antibodies”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO